Table 2 Clinical features of C-Circle positive tumors in the INFORM cohort (n = 40)a.

From: Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome

 

Total cohort

C-Circle positive

C-Circle negative

P valueg

 

No.f

%f

No.f

%f

No.f

%f

 

Total

40

 

19

47.5%

21

52.5%

 

Stage 1-3b

4

10.0%

4

21.1%

0

0.0%

0.041

Stage 4b

34

85.0%

14

73.7%

20

95.2%

 

Stage 4Sb

2

5.0%

1

5.3%

1

4.8%

1.000

LR/IRc

7

17.5%

5

26.3%

2

9.5%

0.226

HRc

33

82.5%

14

73.7%

19

90.5%

 

Male

32

80.0%

13

68.4%

19

90.5%

0.120

Female

8

20.0%

6

31.6%

2

9.5%

 

Aged (mean in days)

1645

 

2243

 

1104

 

0.003

MYCN ampe

11

27.5%

2

10.5%

9

42.9%

0.029

MYCN normale

28

70.0%

17

89.5%

10

47.6%

 
  1. an refers to the number of tumors.
  2. bTumor staging was done according to the INSS criteria.
  3. cRisk stratification was based on the German Neuroblastoma Study NB2004.
  4. dAge at diagnosis.
  5. eMYCN status refers to MYCN status at diagnosis, which is either amplified (amp, ≥8 copies) or normal. MYCN status was inconclusive for one tumor at diagnosis.
  6. fAll values are given in absolute number of tumors (No.) and relative (%) to the total number of tumors in each group (total cohort, C-Circle positive, C-Circle negative).
  7. gP values were calculated using Fisher tests and two-sided Wilcoxon rank sum test (age).
Back to article page